AZN

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.36
Percentage change -0.54	%

Peers: ABBV PFE JNJ MRK NVS BMY GSK SNY LLY AMGN

| Held by: QQQ QQQM FVD DIHP DFIC PPH PVAL TQQQ AVDE QYLD

Scroll to Statements

Index	NDX	P/E	32.00	EPS (ttm)	2.08	Insider Own	0.03%	Shs Outstand	3.10B	Perf Week	-2.38%
Market Cap	206.44B	Forward P/E	14.17	EPS next Y	4.70	Insider Trans	0.00%	Shs Float	3.10B	Perf Month	1.98%
Income	6.50B	PEG	2.67	EPS next Q	1.06	Inst Own	15.79%	Short Float	0.24%	Perf Quarter	-15.76%
Sales	51.21B	P/S	4.03	EPS this Y	13.74%	Inst Trans	-0.32%	Short Ratio	1.38	Perf Half Y	-16.35%
Book/sh	13.13	P/B	5.07	EPS next Y	13.84%	ROA	6.46%	Short Interest	7.40M	Perf Year	1.03%
Cash/sh	1.59	P/C	41.87	EPS next 5Y	12.00%	ROE	16.67%	52W Range	60.47 - 87.68	Perf YTD	-1.14%
Dividend Est.	1.56 (2.34%)	P/FCF	20.74	EPS past 5Y	17.72%	ROI	9.19%	52W High	-24.06%	Beta	0.46
Dividend TTM	1.49 (2.23%)	Quick Ratio	0.71	Sales past 5Y	16.24%	Gross Margin	73.63%	52W Low	10.10%	ATR (14)	1.19
Dividend Ex-Date	Aug 09, 2024	Current Ratio	0.93	EPS Y/Y TTM	10.14%	Oper. Margin	19.83%	RSI (14)	43.80	Volatility	1.24% 1.23%
Employees	89900	Debt/Eq	0.78	Sales Y/Y TTM	13.81%	Profit Margin	12.68%	Recom	1.50	Target Price	86.93
Option/Short	Yes / Yes	LT Debt/Eq	0.74	EPS Q/Q	3.86%	Payout	73.87%	Rel Volume	0.83	Prev Close	66.94
Sales Surprise	3.74%	EPS Surprise	1.83%	Sales Q/Q	18.04%	Earnings	Nov 12 BMO	Avg Volume	5.36M	Price	66.58
SMA20	0.47%	SMA50	-5.40%	SMA200	-11.15%	Trades		Volume	4,452,744	Change	-0.54%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-06-24	Upgrade	Deutsche Bank	Sell → Hold
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy	$97
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight	$85
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold	$78.50 → $70
Dec-18-23	Initiated	HSBC Securities	Buy	$78
Sep-25-23	Upgrade	Jefferies	Hold → Buy	$66.50 → $80
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform	$82
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral
Sep-07-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-29-22	Upgrade	Argus	Hold → Buy	$75
Jun-14-22	Downgrade	UBS	Buy → Neutral

Show Previous Ratings

Dec-11-24 10:21PM	AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption Hagens Berman (GlobeNewswire)
02:10PM	AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients (Benzinga)
10:15AM	LYNPARZA (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial (Business Wire)
Dec-10-24 12:12PM	AstraZenecas (AZN) Struggles: Cramers Disappointment and Challenges in China (Insider Monkey)
09:40AM	Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term (Zacks)
07:00AM	Loading…
Dec-09-24 07:00AM	Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer (Business Wire)
06:37AM	ASH 2024: AstraZeneca set to take a BiTE out of follicular lymphoma market (Clinical Trials Arena)
04:22AM	Priority FDA review given to AstraZenecas Imfinzi sBLA for MIBC (Pharmaceutical Technology)
Dec-08-24 11:00AM	Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial (Business Wire)
Dec-06-24 07:00AM	IMFINZI (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancer (Business Wire)
06:07AM	AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B (BioPharma Dive)
Dec-05-24 10:13AM	FDA Approves AstraZeneca's Blockbuster Cancer Drug Imfinzi For Aggressive Form Of Lung Cancer (Benzinga)
09:50AM	Here's Why Astrazeneca (AZN) is a Strong Momentum Stock (Zacks)
08:22AM	Drugmaker AstraZeneca names new China chief to replace detained executive (CNN Business)
07:13AM	IMFINZI (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer (Business Wire)
04:37AM	Loading…
04:37AM	FDA approves AstraZenecas Imfinzi to treat LS-SCLC (Pharmaceutical Technology)
Dec-04-24 03:25PM	AstraZeneca Appoints Iskra Reic as International EVP Amid Chinese Investigation; Stock Down 3.8% YTD (GuruFocus.com)
12:20PM	AstraZeneca appoints new China head after long-standing executive detained (Financial Times)
Dec-03-24 02:01AM	How Alexion markets a rare disease drug by starting with the end in mind (Pharma Voice)
Dec-02-24 09:03PM	Lightning Round: Take a pass on AstraZeneca, says Jim Cramer (CNBC TV)
07:46AM	Why AstraZeneca PLC (AZN) Is One of the Most Profitable Pharmaceutical Stocks Right Now? (Insider Monkey)
07:43AM	Analyst Report: AstraZeneca PLC (Morningstar Research)
Nov-30-24 11:27AM	Why AstraZeneca PLC (AZN) Is One of the Best ADR Stocks to Invest in? (Insider Monkey)
Nov-28-24 07:04AM	Fasenra shows benefit in acute asthma and COPD in Phase II trial (Clinical Trials Arena)
Nov-26-24 12:41PM	Failure of AstraZenecas AZD4041 a blow for non-opioid OUD treatments (Clinical Trials Arena)
05:32AM	AstraZeneca reports results from trial of combination therapy for prostate cancer (Clinical Trials Arena)
Nov-25-24 01:48PM	AstraZeneca PLC (NASDAQ:AZN) Focuses on Growth in the U.S.: Is It the Best Time to Invest In AZN? (Insider Monkey)
07:00AM	TRUQAP (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial (Business Wire)
05:18AM	GCAR and AstraZeneca execute agreement to evaluate AZD1390 for glioblastoma (Clinical Trials Arena)
04:23AM	AstraZeneca PLC (AZN): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
10:23AM	Loading…
Nov-23-24 10:23AM	AstraZeneca (AZN): A Top Pick for Hedge Funds Due to Innovation and Rising Demand (Insider Monkey)
Nov-21-24 04:57AM	3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now (Motley Fool)
04:36AM	AstraZeneca upgraded to Neutral from Sell at UBS (TipRanks)
04:30AM	AstraZeneca price target lowered to EUR 140 from EUR 150 at Berenberg (TipRanks)
Nov-20-24 07:30AM	AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US (Business Wire)
07:23AM	Daiichi Sankyo and AstraZenecas Enhertu snubbed by UKs NICE for third time (Pharmaceutical Technology)
06:05AM	AstraZeneca Is No Longer a Sell for Any Analyst as UBS Upgrades (Bloomberg)
Nov-19-24 06:35AM	AstraZenecas Tagrisso recommended for approval in EU by CHMP for certain NSCLC (TipRanks)
04:06AM	CHMP recommends AstraZenecas Tagrisso for EU approval for NSCLC (Pharmaceutical Technology)
Nov-18-24 04:01PM	GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study (PR Newswire)
10:32AM	AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership (Pharmaceutical Technology)
09:45AM	Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
08:34AM	Is AstraZeneca PLC (AZN) the Best Immunotherapy Stock to Buy Now? (Insider Monkey)
04:30AM	Is AstraZeneca PLC (AZN) A Cheap NASDAQ Stock To Invest In Now? (Insider Monkey)
12:40AM	Analyst Report: AstraZeneca PLC (Morningstar Research)
Nov-15-24 04:18PM	How analysts are reacting to RFK Jr. as Trump's HHS pick (Yahoo Finance Video)
12:15PM	Stocks to Watch Friday: Applied Materials, Alibaba, Domino's, Novo Nordisk (The Wall Street Journal)
12:04PM	Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head (Investopedia)
11:15AM	Trumps RFK Jr. Pick Weighs on Vaccine Makers (The Wall Street Journal)
09:43AM	Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of. (Yahoo Finance)
08:46AM	Ouch: Why a Healthcare Selloff Really Hurts in Europe (The Wall Street Journal)
08:34AM	Heard on the Street: RFK Jr. Is Spooking Obesity Investors Too (The Wall Street Journal)
06:45AM	RFK Jr. News Hits Global Pharma Stocks (The Wall Street Journal)
Nov-14-24 07:15AM	Is AstraZeneca a Buy as It Eyes the Weight Loss Market? (Motley Fool)
12:00AM	China has trapped the tiger of AstraZenecas growth (Financial Times)
Nov-13-24 10:22AM	Q3 2024 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
10:06AM	Analyst Report: AstraZeneca PLC (Morningstar Research)
07:17AM	AstraZeneca and Daiichi Sankyo submit BLA to FDA for lung cancer treatment (Pharmaceutical Business Review)
06:56AM	Merck and AstraZeneca announce results of Koselugo in neurofibromatosis trial (TipRanks)
06:15AM	Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing (BioPharma Dive)
05:42AM	AstraZeneca invests $3.5B in US manfacturing, R&D (Manufacturing Dive)
05:26AM	MSD and AstraZeneca report positive topline data from Koselugo trial for NF1 (Clinical Trials Arena)
04:44AM	AstraZeneca plans major $3.5bn expansion drive in the US (Investment Monitor)
02:12AM	AstraZeneca PLC (AZN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Nov-12-24 09:23PM	Q3 2024 Absci Corp Earnings Call (Thomson Reuters StreetEvents)
04:45PM	AstraZeneca Plc (AZN) Q3 2024 Earnings Call Transcript (Motley Fool)
04:13PM	AstraZeneca Reverses As Beat And Raise Outweighs Drug Smuggling Claims (Investor's Business Daily)
02:57PM	AstraZeneca Expands U.S. Investment Plan (The Wall Street Journal)
01:15PM	FTSE 100 drops to three-month low amid global sell-off (The Telegraph)
11:53AM	Are dry powder inhalers the key to sustainable respiratory care? (Medical Device Network)
11:53AM	Are dry powder inhalers really the key to sustainable respiratory care? (Pharmaceutical Technology)
11:42AM	AstraZeneca Dips As Drug Smuggling Allegations Undo Third-Quarter Beat And Raise (Investor's Business Daily)
10:20AM	AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously' (Benzinga)
09:49AM	AstraZeneca Stock Dives As China's Criminal Probe Rattles Its Third-Quarter Beat (Investor's Business Daily)
09:46AM	AstraZenecas £450m UK investment under review in state aid stand-off (The Telegraph)
09:46AM	AstraZeneca puts £450m UK investment on hold in state aid stand-off (The Telegraph)
09:30AM	Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q3 Earnings (Zacks)
08:44AM	AstraZeneca Lifts Outlook, Plans $3.5B US Investment (Investopedia)
07:31AM	AstraZeneca chief taking arrest of Chinese executive very seriously (The Telegraph)
07:00AM	AstraZenecas 9M and Q3 2024 results (Business Wire)
07:00AM	AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States (Business Wire)
05:49AM	AstraZeneca Raises Outlook, Plans U.S. Investment (The Wall Street Journal)
05:02AM	Astrazeneca: Q3 Earnings Snapshot (Associated Press Finance)
02:33AM	AstraZeneca Q3 Net Income Rises; Upgrades 2024 Guidance (RTT News)
02:27AM	AstraZeneca Raises Outlook on Earnings, Sales Beat (The Wall Street Journal)
02:05AM	AstraZeneca lifts 2024 outlook after Q3 beat, doubles down on US investments (Reuters)
Nov-11-24 04:56PM	Home Depot earnings, YF Invest: What to Watch (Yahoo Finance Video)
07:03AM	Earnings To Watch: AstraZeneca PLC (OSTO:AZN) Reports Q3 2024 Result (GuruFocus.com)
Nov-10-24 07:55AM	What To Expect in the Markets This Week (Investopedia)
06:11AM	Is AstraZeneca PLC (AZN) The Best UK Stock to Invest in Now? (Insider Monkey)
Nov-08-24 05:24PM	Disney earnings, CPI, Yahoo Finance Invest: What To Watch (Yahoo Finance Video)
09:52AM	AstraZeneca and Amgens Tezspire succeeds in Phase III nasal polyps trial (Pharmaceutical Technology)
09:33AM	Analyst Report: AstraZeneca PLC (Morningstar Research)
08:47AM	AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis (Benzinga)
07:00AM	TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (Business Wire)
05:00AM	Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value (BioPharma Dive)
05:00AM	AstraZenecas China-Fueled Plunge May Be Difficult to Shake Off (Bloomberg)
Nov-07-24 06:15PM	Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
09:15AM	Unveiling Astrazeneca (AZN) Q3 Outlook: Wall Street Estimates for Key Metrics (Zacks)
07:00AM	AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024 (Business Wire)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Astrazeneca plc ADR

Upgrade your FINVIZ experience